CymaBay Therapeutics Inc (CBAY) : Omega Fund Management reduced its stake in CymaBay Therapeutics Inc by 6.75% during the most recent quarter end. The investment management company now holds a total of 606,100 shares of CymaBay Therapeutics Inc which is valued at $1,472,823 after selling 43,900 shares in CymaBay Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 2, 2016.CymaBay Therapeutics Inc makes up approximately 1.15% of Omega Fund Management’s portfolio.
CymaBay Therapeutics Inc (CBAY) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $2.44 and reached the intraday high at $2.54. The bulls started the profit booking and pushed the shares to intraday low of $2.36. The trading session was marked by a volume range of 99,971 shares exchanging hands. The 52-week high of the shares is $5 and the 52-week low is $0.8201. The market cap of the company stands at $57 M and there are 2,34,47,003 shares in public circulation.
Other Hedge Funds, Including ,
CymaBay Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases including serious rare and orphan disorders. Arhalofenate the Company’s lead product candidate is used to treat gout. The Company has completed five Phase II clinical trials of Arhalofenate in patients with gout. The Company’s second product candidate MBX-8025 is used to treat disorder linked to deficits in lipid storage handling and utilization many of which result in metabolic disorders. The Company has completed five Phase I and one Phase II clinical trials of MBX-8025. The Company’s MBX-2982 is a treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119) a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 has completed four Phase I studies and one Phase II study.